Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell Corporation (Nasdaq: ICCC) reported a 11% increase in product sales to $4.9 million for Q1 2020, compared to the same period in 2019. The First Defense® product line saw a 16% increase in sales. However, the company experienced a net loss of $122,000, or $0.02 per share, in contrast to a net income of $145,000, or $0.03 per share, in Q1 2019. A significant backlog of orders reached $1.4 million due to increased demand. Management is completing a facility expansion to boost production capacity from $18 million to $27 million.